2026-04-17T03:05:06Zhttps://recercat.cat/oai/request

oai:recercat.cat:10230/450632025-12-19T22:58:43Zcom_2072_6col_2072_452952

00925njm 22002777a 4500 dc Boronat Rigol, Anna, 1990- author Mateus Rodriguez, Julian Andrés author Soldevila-Domenech, Natalia author Guerra Albà, Mercè author Rodríguez-Morató, Jose, 1987- author Varon, Carlota author Muñoz, Daniel author Barbosa, Francina author Morales, Juan Carlos author Gaedigk, Andreas author Langohr, Klaus author Covas Planells, Maria Isabel author Pérez Mañá, Clara author Fitó Colomer, Montserrat author Tyndale, Rachel F. author Torre Fornell, Rafael de la author 2020-07-03T06:46:40Z 2020-07-03T06:46:40Z 2019 Here we present new and original data on the endogenous conversion of tyrosol (Tyr) into hydroxytyrosol (OHTyr) in humans and its effects on the cardiovascular system. A randomized, crossover, controlled clinical trial was performed with individuals at cardiovascular risk (n = 33). They received white wine (WW) (females 1, males 2 standard drinks/day), WW plus Tyr capsules (WW + Tyr) (25mg Tyr capsule, one per WW drink), and water (control) ad libitum. Intervention periods were of 4 weeks preceded by three-week wash-out periods. We assessed the conversion of Tyr to OHTyr, its interaction with a polygenic activity score (PAS) from CYP2A6 and CYP2D6 genotypes, and the effects on cardiovascular risk markers. For further details and experimental findings please refer to the article "Cardiovascular benefits of tyrosol and its endogenous conversion into hydroxytyrosol in humans. A randomized, controlled trial" CYP2A6 CYP2D6 Cardiovascular risk Endogenous conversion Hydroxytyrosol Tyrosol Data on the endogenous conversion of tyrosol into hydroxytyrosol in humans